På fredag är det seriepremiär. Och för första gången i hela mitt liv kommer jag och pappa inte diskutera utgången. Cancer och alzheimers är två fruktansvärt brutala sjukdomar. Flyg högt, älskade pappa❤️ https://t.co/GcDhrTGTKL #cancer #alzheimers #kärlek
Hugo Lövheim, professor of geriatric medicine at Umeå University, is awarded the Inga Sandeborg Prize 2026 for his significant research on the connection between herpes viruses and Alzheimer's disease. (translated)
Israeli scientists have generated novel remedies for cancer, Alzheimer’s and so many other diseases. Maybe we can cure this too, if we apply ourselves? #CancerResearch #Alzheimers #MedicalInnovation #IL
A new study from Karolinska Institutet shows that modern anticoagulant drugs of the NOAC type can be associated with a slower cognitive decline in people suffering from both atrial fibrillation and Alzheimer's disease. (translated)
Bioarctics partner Eisai presenterade på AAIC 2026 nya data som visar att den subkutana autoinjektorformuleringen av Leqembi erbjuder likvärdig effekt och säkerhet som intravenös behandling för patienter med tidig Alzheimers sjukdom. #Bioarctic #Alzheimers #Läkemedel
Politiet søger en 82-årig mand med Alzheimers, der er forsvundet fra sit hjem i Silkeborg og sidst set løbe ind i en skov ved Vestre Ringvej, og familien beder om hjælp til at finde ham. #Alzheimers #eftersøgning #Silkeborg
Politiet leder efter en 82-årig mand med Alzheimers, der forlod sit hjem i Silkeborg og blev sidst set løbe ind i en nærliggende skov. #Alzheimers #Silkeborg #eftersøgning
En ny studie från Karolinska Institutet visar att en hälsosammare kost kan vara kopplad till en lägre demensrisk hos äldre vuxna, särskilt de med förhöjda biologiska riskmarkörer för Alzheimers sjukdom. #hälsosamkost #demensrisk #äldre
Impressive study suggesting that hyperglycosylation (addition of sugars to proteins) may be a driver of Alzheimer’s disease 👀 They also show that glucosamine supplements (often used for joint health) are associated with Alzheimer’s progression and mortality. #Alzheimers #HealthResearch #Glucosamine #Therearenospecificcountriesmentionedinthetweet.
Alzheimer’s affects memory, identity & independence with a huge impact on patients, families & caregivers. In my message at MindShift in 🇮🇹, I underlined 🇪🇺 support for prevention, diagnosis & care from brain health research to the #SafeHeartsPlan, #medicaldevices & #BiotechAct. https://t.co/fPIE8Q5LKT #Alzheimers #BrainHealth #Caregiving #IT #EU
From my husband’s dementia journey comes a guide for caregivers—tools, resources, and lessons learned. 💜 #DementiaCare #CaregiverSupport https://t.co/36fAXyyax5 #DementiaCare #CaregiverSupport #AlzheimersAwareness #Thetweetdoesnotmentionanyspecificcountries.Therefore #therearenocountrycodestoreturn.
Roche announced that Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, has received CE Mark clearance for use in Europe, offering a faster and simpler diagnostic tool for millions of patients and potentially reducing the burden on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH #US
Roche announced that Elecsys pTau217, the first blood test specifically designed to signal and rule out Alzheimer's disease, has received CE Mark approval for use in Europe, promising faster diagnoses for millions of patients by detecting pTau217 protein levels, thereby indicating the likelihood of Alzheimer's while potentially reducing the need for more invasive testing. #AlzheimersDisease #Diagnostics #HealthcareInnovation #EU #CH
Roche has received clearance for Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease in Europe, which promises faster diagnoses for millions of patients by detecting levels of a protein linked to the disease. #AlzheimersDisease #BloodTest #HealthcareInnovation #EU #CH #US
Roche has announced that the Elecsys pTau217 blood test, developed in collaboration with Eli Lilly and Company and now cleared for use in Europe, offers a rapid and effective method for diagnosing or ruling out Alzheimer's disease, potentially aiding millions of patients while reducing the burden on healthcare systems. #Alzheimers #BloodTest #Healthcare #EU #CH #US
Roche announced the European clearance of Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease, which offers a quicker diagnostic tool for millions of patients and aims to simplify the diagnostic process for physicians by indicating the likelihood of Alzheimer’s presence based on pTau217 protein levels. #Alzheimers #HealthcareInnovation #BloodTest #EU #CH #US
Roche announced the approval of Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, which is now cleared for use in Europe, offering a faster and simpler diagnostic tool that can significantly improve early detection for patients and alleviate pressure on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH
Roche announced the clearance of Elecsys pTau217, the first blood test specifically designed to detect and rule out Alzheimer's disease, which is now authorized for use in Europe, promising faster diagnoses and improved support for patients and families navigating the challenges of the disease. #Alzheimers #Diagnostics #Healthcare #EU #CH #US
